BioSpace News Archive

Business

The FDA Is Approving Drugs Faster, But That May Not Be A Good Thing

The study notes that about half of recent drug approvals were built on a single pivotal clinical trial. Typically, two pivotal, Phase III trials were the norm.

January 30, 2020
·
4 min read
·
Mark Terry
BioCapital

Research Roundup: Eating an Egg a Day is Healthy and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

January 30, 2020
·
4 min read
·
Mark Terry
Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

Latest approval for apalutamide could benefit a population of more than 100,000 people living with mHSPC across Europe.

January 30, 2020
·
2 min read
Novartis Writes Off Advair Copycat Program, Posts Strong Q4 Results

In its annual report, Novartis said it has stopped working on the years-long project and will record a $442 million impairment charge as a result.

January 30, 2020
·
3 min read
·
Alex Keown
Policy

NIH Grants $4.8 Million to Gladstone Institutes to Study ApoE4 in Alzheimer’s

The focus of the research will be to learn more about ApoE4 and how and why it affects Alzheimer’s disease.

January 30, 2020
·
3 min read
·
Mark Terry
Ponder If You Will, Your Legacy

As you build your career strategy, one thing to keep in mind is how you want to be remembered. What do you want to be known for? Answer this question as you map out your goals.

January 30, 2020
·
1 min read
·
BioSpace Staff
Pharm Country

NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy Achieved the Secondary Endpoint of Overall Survival (OS) in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Results from the preplanned final overall survival analysis of the Phase III ARAMIS trial that investigated NUBEQA® in men with non-metastatic castration-resistant prostate cancer show a significant improvement in overall survival in patients receiving NUBEQA plus androgen deprivation therapy compared to placebo plus ADT.

January 30, 2020
·
6 min read
Drug Development

Isofol Medical: Over 200 Patients Now Randomized in the Global Phase 3 AGENT Study

Isofol Medical AB, announced that over 200 patients of the planned 440 has been randomized in the global Phase 3 AGENT Study.

January 30, 2020
·
3 min read
Deals

ERBA Mannheim Poised to Be Game Changer in Total Lab Automation at Medlab Middle East 2020

10 New launches at MEDLAB ME exhibition positions Erba as a complete end-to-end provider.

January 30, 2020
·
2 min read
Business

Applied DNA Schedules Fiscal 2020 First Quarter Financial Results Conference Call for Thursday, February 6, 2020 at 4:30 PM ET

Applied DNA Sciences, Inc., announced it plans to release financial results for its fiscal 2020 first quarter ended December 31, 2019 after market close on Thursday, February 6, 2020.

January 30, 2020
·
2 min read